Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes

Geriatrics & Gerontology International
Takashi OkamotoMasahiro Akishita

Abstract

We aimed to determine the feasibility of substituting thiazolidinedione-based therapy for insulin injection therapy in patients with type 2 diabetes. Thirty-six subjects (17 men and 19 women) aged 67.8 +/- 11.3 years with an average insulin dose of 0.46 +/- 0.17 U/kg bodyweight, a duration of insulin therapy of 6.1 +/- 8.2 years and an average hemoglobin A1c (HbA1c) of 6.8 +/- 1.3% were switched from insulin injection therapy to pioglitazone, glimepiride and voglibose combination therapy. The number of subjects achieving HbA1c levels of less than 7% at 4 months was 30. The success rate of switch therapy was 83% (30/36). HbA1c was significantly reduced from 6.7 +/- 1.3% to 5.9 +/- 0.7% at 4 months after the switch (P < 0.01) in 32 patients who completed the planned 4-month study. No adverse effects including heart failure, liver dysfunction or severe hypoglycemia were observed. The insulin dose and the maximum blood glucose on the switch day were significantly lower and the age was significantly higher in the subjects who achieved HbA1c less than 7% at 4 months compared to those who did not (P < 0.05). Thiazolidinedione-based oral combination therapy may efficiently and safely substitute relatively high-dose insulin injection th...Continue Reading

References

Dec 1, 1991·Diabetes Care·M P Stern, S M Haffner
Apr 11, 1996·The New England Journal of Medicine·J P DesprésP J Lupien
Jan 26, 1999·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·H IshidaY Seino
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Dec 22, 1999·Neurology·A OttM M Breteler
Oct 3, 2001·American Journal of Epidemiology·J A LuchsingerR Mayeux
Feb 5, 2004·American Heart Journal·Darren K McGuireUNKNOWN SYMPHONY and 2nd SYMPHONY Investigators
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Oct 13, 2004·Neurology·Jose A LuchsingerRichard Mayeux
Apr 30, 2005·Diabetes Research and Clinical Practice·Ikuyoshi WatanabeKatsuo Kanmatsuse
Jul 30, 2005·Diabetes, Obesity & Metabolism·Roderick E Warren, Brian M Frier
Dec 20, 2005·Lancet Neurology·Geert Jan BiesselsPhilip Scheltens
Jan 10, 2006·Drugs·John WaughDean M Robinson
Jan 25, 2006·The Journal of Biological Chemistry·Naoto KubotaTakashi Kadowaki
Mar 16, 2006·The Journal of Medical Investigation : JMI·Kunihiko KoshibaSusumu Ito
Apr 20, 2006·Diabetes Research and Clinical Practice·Masashi KobayashiUNKNOWN Japan Diabetes Clinical Data Management Study Group
Oct 17, 2006·Drugs·Emma D Deeks, Lesley J Scott

❮ Previous
Next ❯

Citations

Apr 30, 2013·Current Diabetes Reports·Hanford YauKenneth Cusi
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Stanley S Schwartz
Oct 5, 2010·Geriatrics & Gerontology International·Naoki SajiKoichi Yokono
Apr 23, 2013·JAAPA : Official Journal of the American Academy of Physician Assistants·Alexis Nixon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Caveolins & Signal Transduction

Caveolins are small proteins with a hairpin loop conformation that are located in the plasma membrane of various cell types where they bind cholesterol and interact with receptors essential for several signal transduction pathways. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.